347 filings
Page 4 of 18
424B5
tcco xpsfru
13 Sep 18
Prospectus supplement for primary offering
12:00am
8-K
3b2i3b 8mhefma0
13 Sep 18
Termination of a Material Definitive Agreement
12:00am
424B5
b8uvld8qwzmy50ntl2pl
12 Sep 18
Prospectus supplement for primary offering
12:00am
8-K
9qkwo1bfbn71yg97t7io
12 Sep 18
Other Events
12:00am
CT ORDER
ba3ndfrrbr3pcnmop cd
11 Sep 18
Confidential treatment order
12:00am
8-K
uwa8lv1rhj
11 Sep 18
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
12:00am
8-K
ycu63avw2gx zx6
6 Sep 18
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
12:00am
8-K
z0y3cdb
29 Aug 18
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
12:00am
SC 13G/A
yd2wpu
10 Aug 18
Xenon Pharmaceuticals Inc.
1:01pm
8-K
i0l835utt5n14wc8z
7 Aug 18
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
4:51pm
8-K
3orcxg83ozr
7 Aug 18
Entry into a Material Definitive Agreement
12:00am
SC 13G
8gu662
13 Jul 18
Xenon Pharmaceuticals Inc.
1:59pm
8-K
o9io5cqtjkhisf
12 Jul 18
Entry into a Material Definitive Agreement
6:05am
424B5
vrhnorc6n
11 Jul 18
Prospectus supplement for primary offering
9:59pm
8-K
1nf3dlvp5
3 Jul 18
Other Events
3:35pm
SC 13G
7k3xk9excf669onkp
3 Jul 18
Xenon Pharmaceuticals Inc.
12:56pm
4
0ynu ms6fbc9y2
22 Jun 18
Xenon Pharmaceuticals / MICHAEL M TARNOW ownership change
4:40pm
4
wtdenzwvotj0gz 9tw
22 Jun 18
Xenon Pharmaceuticals / MOHAMMAD AZAB ownership change
4:39pm
4
63zazjeimq7
15 Jun 18
Xenon Pharmaceuticals / GARY PATOU ownership change
7:32pm